Applicability of Redirecting Artemisinins for New Targets.

Autor: Golenser J; Department of Microbiology and Molecular Genetics Kuvin Center for the Study of Infectious and Tropical Diseases The Hebrew University - Hadassah Medical Center Jerusalem Israel., Hunt NH; School of Medical Sciences University of Sydney Sydney 2050 Australia., Birman I; Department of Microbiology and Molecular Genetics Kuvin Center for the Study of Infectious and Tropical Diseases The Hebrew University - Hadassah Medical Center Jerusalem Israel., Jaffe CL; Department of Microbiology and Molecular Genetics Kuvin Center for the Study of Infectious and Tropical Diseases The Hebrew University - Hadassah Medical Center Jerusalem Israel., Zech J; Institute of Pharmacy Martin Luther University Halle-Wittenberg 06108 Halle Germany., Mäder K; Institute of Pharmacy Martin Luther University Halle-Wittenberg 06108 Halle Germany., Gold D; Department of Clinical Microbiology and Immunology Faculty of Medicine Tel Aviv University Tel Aviv Israel.
Jazyk: angličtina
Zdroj: Global challenges (Hoboken, NJ) [Glob Chall] 2023 Oct 27; Vol. 7 (12), pp. 2300030. Date of Electronic Publication: 2023 Oct 27 (Print Publication: 2023).
DOI: 10.1002/gch2.202300030
Abstrakt: Employing new therapeutic indications for drugs that are already approved for human use has obvious advantages, including reduced costs and timelines, because some routine steps of drug development and regulation are not required. This work concentrates on the redirection of artemisinins (ARTS) that already are approved for clinical use, or investigated, for malaria treatment. Several mechanisms of action are suggested for ARTS, among which only a few have been successfully examined in vivo, mainly the induction of oxidant stress and anti-inflammatory effects. Despite these seemingly contradictory effects, ARTS are proposed for repurposing in treatment of inflammatory disorders and diverse types of diseases caused by viral, bacterial, fungal, and parasitic infections. When pathogens are treated the expected outcome is diminution of the causative agents and/or their inflammatory damage. In general, repurposing ARTS is successful in only a very few cases, specifically when a valid mechanism can be targeted using an additional therapeutic agent and appropriate drug delivery. Investigation of repurposing should include optimization of drug combinations followed by examination in relevant cell lines, organoids, and animal models, before moving to clinical trials.
Competing Interests: The authors declare no conflict of interest.
(© 2023 The Authors. Global Challenges published by Wiley‐VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: